
Opinion|Videos|July 18, 2024
Emerging Breast Cancer Therapies and Closing Thoughts
A leading oncologist explores promising new breast cancer therapies in the drug development pipeline and advises healthcare providers on strategies to remain informed about the most current treatment guidelines and recommendations.
Advertisement
Episodes in this series

- What drug developments are targeting unmet needs in breast cancer treatment? What drugs are currently in the pipeline that you are excited about?
- How can healthcare providers stay updated with the latest breast cancer treatment guidelines?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5














































